When evaluating mono-target therapies, we found over-expressing TNF-α, instead of blocking it, was associated with a decreased activation of Ang2 and Thrombosis, which can be related to decreased organ dysfunctions. The gene discussed is ANGPT2; the disease is Venous thrombosis.